Exosomal noncoding RNAs in gynecological cancers: implications for therapy resistance and biomarkers.

Changfen Xu, Peiyao Xu, Jiaqi Zhang, Sheng He, Tingting Hua, Aiwu Huang
Author Information
  1. Changfen Xu: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  2. Peiyao Xu: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  3. Jiaqi Zhang: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  4. Sheng He: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  5. Tingting Hua: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
  6. Aiwu Huang: Department of Gynecology and Obstetrics , Hangzhou Lin'an Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.

Abstract

Gynecologic cancers, including ovarian cancer (OC), cervical cancer (CC), and endometrial cancer (EC), pose a serious threat to women's health and quality of life due to their high incidence and lethality. Therapeutic resistance in tumors refers to reduced sensitivity of tumor cells to therapeutic drugs or radiation, which compromises the efficacy of treatment or renders it ineffective. Therapeutic resistance significantly contributes to treatment failure in gynecologic tumors, although the specific molecular mechanisms remain unclear. Exosomes are nanoscale vesicles released and received by distinct kinds of cells. Exosomes contain proteins, lipids, and RNAs closely linked to their origins and functions. Recent studies have demonstrated that exosomal ncRNAs may be involved in intercellular communication and can modulate the progression of tumorigenesis, aggravation and metastasis, tumor microenvironment (TME), and drug resistance. Besides, exosomal ncRNAs also have the potential to become significant diagnostic and prognostic biomarkers in various of diseases. In this paper, we reviewed the biological roles and mechanisms of exosomal ncRNAs in the drug resistance of gynecologic tumors, as well as explored the potential of exosomal ncRNAs acting as the liquid biopsy molecular markers in gynecologic cancers.

Keywords

References

  1. Signal Transduct Target Ther. 2023 Mar 15;8(1):124 [PMID: 36922504]
  2. Drug Resist Updat. 2023 May;68:100960 [PMID: 37003125]
  3. J Control Release. 2023 Jun;358:98-115 [PMID: 37120033]
  4. Int J Biol Sci. 2018 Nov 1;14(14):1960-1973 [PMID: 30585260]
  5. Theranostics. 2023 Jul 24;13(12):4266-4286 [PMID: 37554270]
  6. Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188982 [PMID: 37734560]
  7. Med Res Rev. 2021 May;41(3):1751-1774 [PMID: 33368430]
  8. Mol Cancer. 2022 Sep 13;21(1):179 [PMID: 36100944]
  9. Mol Cancer. 2023 Jun 15;22(1):96 [PMID: 37322433]
  10. J Exp Clin Cancer Res. 2019 Feb 15;38(1):81 [PMID: 30770776]
  11. Trends Pharmacol Sci. 2022 Apr;43(4):269-280 [PMID: 35153075]
  12. Cell Mol Life Sci. 2023 Aug 17;80(9):256 [PMID: 37589744]
  13. Biochim Biophys Acta Rev Cancer. 2022 Nov;1877(6):188811 [PMID: 36208648]
  14. Clin Cancer Res. 2023 May 15;29(10):1969-1983 [PMID: 36795892]
  15. Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101 [PMID: 31234009]
  16. J Control Release. 2023 Jan;353:327-336 [PMID: 36464063]
  17. Int J Mol Med. 2020 Aug;46(2):609-620 [PMID: 32626953]
  18. Cancer Res. 2023 Mar 15;83(6):809-813 [PMID: 36919419]
  19. Semin Cancer Biol. 2022 Nov;86(Pt 3):189-198 [PMID: 35276341]
  20. Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33 [PMID: 31479922]
  21. Nat Methods. 2022 Oct;19(10):1208-1220 [PMID: 35618955]
  22. Front Endocrinol (Lausanne). 2023 Jun 26;14:1199569 [PMID: 37455911]
  23. Nat Cancer. 2023 Sep;4(9):1239-1257 [PMID: 37653142]
  24. Cell Metab. 2021 Sep 7;33(9):1744-1762 [PMID: 34496230]
  25. J Gynecol Oncol. 2024 Mar;35(2):e13 [PMID: 37921598]
  26. Nat Protoc. 2022 Nov;17(11):2517-2549 [PMID: 35962195]
  27. Front Genet. 2022 Jun 30;13:850089 [PMID: 35910206]
  28. Semin Cancer Biol. 2022 Nov;86(Pt 1):13-25 [PMID: 34517111]
  29. Adv Sci (Weinh). 2022 Oct;9(28):e2203357 [PMID: 35978266]
  30. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188914 [PMID: 37201730]
  31. Semin Cancer Biol. 2021 Sep;74:79-91 [PMID: 33798721]
  32. Trends Mol Med. 2022 May;28(5):405-420 [PMID: 35379558]
  33. Lancet HIV. 2023 Jun;10(6):e412-e420 [PMID: 37182539]
  34. Cell Death Differ. 2021 Feb;28(2):715-729 [PMID: 32929219]
  35. J Ovarian Res. 2021 Apr 28;14(1):59 [PMID: 33910598]
  36. Biosens Bioelectron. 2022 Oct 15;214:114554 [PMID: 35834978]
  37. ACS Nano. 2023 May 9;17(9):8108-8122 [PMID: 37129374]
  38. Pharmacol Res. 2021 Sep;171:105785 [PMID: 34311072]
  39. Cytokine Growth Factor Rev. 2023 Oct;73:114-134 [PMID: 37419767]
  40. Cochrane Database Syst Rev. 2022 Sep 26;9:CD015048 [PMID: 36161421]
  41. BMJ. 2022 Dec 15;379:e070115 [PMID: 36521855]
  42. Drug Resist Updat. 2023 May;68:100962 [PMID: 37068396]
  43. EBioMedicine. 2018 Dec;38:100-112 [PMID: 30487062]
  44. Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990060 [PMID: 33550924]
  45. Cancer Res. 2023 May 15;83(10):1611-1627 [PMID: 36939397]
  46. Trends Cancer. 2023 Nov;9(11):937-954 [PMID: 37558577]
  47. Trends Immunol. 2022 Nov;43(11):917-931 [PMID: 36220689]
  48. Drug Discov Today. 2023 Sep;28(9):103690 [PMID: 37379906]
  49. Nanoscale Horiz. 2022 Mar 28;7(4):352-367 [PMID: 35043812]
  50. Small. 2023 Apr;19(17):e2205739 [PMID: 36592424]
  51. Clin Transl Med. 2021 May;11(5):e425 [PMID: 34047469]
  52. J Ovarian Res. 2022 Feb 19;15(1):27 [PMID: 35183243]
  53. Reprod Sci. 2022 Jun;29(6):1809-1821 [PMID: 35334101]
  54. Semin Cancer Biol. 2022 Nov;86(Pt 1):101-111 [PMID: 34384877]
  55. Biomolecules. 2021 Nov 14;11(11): [PMID: 34827689]
  56. Cancers (Basel). 2022 Mar 29;14(7): [PMID: 35406505]
  57. Curr Probl Cardiol. 2023 Jun;48(6):101637 [PMID: 36773949]
  58. Mol Cancer. 2022 Feb 18;21(1):56 [PMID: 35180868]
  59. Autoimmun Rev. 2023 Mar;22(3):103260 [PMID: 36565798]
  60. J Ovarian Res. 2018 Sep 15;11(1):81 [PMID: 30219071]
  61. Mol Cancer. 2022 Jan 7;21(1):13 [PMID: 34996480]
  62. Theranostics. 2021 Jan 1;11(7):3183-3195 [PMID: 33537081]
  63. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188908 [PMID: 37172650]
  64. Eur J Cancer. 2021 Feb;144:252-268 [PMID: 33373870]
  65. Sci China Life Sci. 2024 Jan;67(1):19-40 [PMID: 37728804]
  66. Aging (Albany NY). 2020 Oct 7;12(19):19095-19106 [PMID: 33028742]
  67. Trends Plant Sci. 2024 Feb 16;: [PMID: 38368122]
  68. Small. 2023 Jun 20;:e2303772 [PMID: 37340569]
  69. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231198348 [PMID: 37981789]
  70. J Ovarian Res. 2019 Jan 22;12(1):6 [PMID: 30670062]
  71. Med Mol Morphol. 2023 Mar;56(1):38-45 [PMID: 36367588]
  72. J Clin Med. 2021 May 13;10(10): [PMID: 34068397]
  73. JAMA. 2023 Aug 8;330(6):547-558 [PMID: 37552298]
  74. J Exp Clin Cancer Res. 2019 Oct 30;38(1):437 [PMID: 31666098]
  75. Acta Pharm Sin B. 2021 Aug;11(8):2136-2149 [PMID: 34522581]
  76. Int J Biol Sci. 2023 May 29;19(9):2879-2896 [PMID: 37324939]
  77. Am J Obstet Gynecol. 2023 Aug;229(2):93-100 [PMID: 37001577]
  78. Mol Ther Nucleic Acids. 2022 Jan 10;27:824-837 [PMID: 35141044]
  79. Cell Biol Int. 2021 Oct;45(10):2140-2149 [PMID: 34288231]
  80. Bioeng Transl Med. 2020 Jul 16;5(3):e10172 [PMID: 33005738]
  81. Front Oncol. 2022 Dec 14;12:986343 [PMID: 36591520]
  82. Bioeng Transl Med. 2022 Jun 28;8(1):e10343 [PMID: 36684081]
  83. J Hematol Oncol. 2020 Nov 10;13(1):152 [PMID: 33168028]
  84. J Exp Clin Cancer Res. 2020 Nov 4;39(1):231 [PMID: 33148302]
  85. Neoplasma. 2023 Dec;70(6):713-721 [PMID: 37962863]
  86. Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188894 [PMID: 37011697]
  87. Cytokine Growth Factor Rev. 2023 Oct;73:135-149 [PMID: 37543438]
  88. Cancer Biomark. 2019;26(4):491-500 [PMID: 31658043]
  89. Semin Cancer Biol. 2022 Nov;86(Pt 1):80-100 [PMID: 35192929]
  90. Cytokine Growth Factor Rev. 2023 Oct;73:163-172 [PMID: 37541790]
  91. J Oncol. 2023 Feb 6;2023:6341011 [PMID: 36793374]
  92. Lancet Public Health. 2023 Apr;8(4):e248-e249 [PMID: 36965976]
  93. Cochrane Database Syst Rev. 2023 Apr 18;4:CD007930 [PMID: 37185961]
  94. Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188888 [PMID: 37001618]
  95. Mol Cancer. 2022 Jan 14;21(1):15 [PMID: 35031075]
  96. Nat Rev Cancer. 2023 Oct;23(10):673-685 [PMID: 37500767]
  97. J Control Release. 2022 Jul;347:533-543 [PMID: 35597405]
  98. JAMA Oncol. 2023 Jun 1;9(6):851-859 [PMID: 37079311]
  99. JAMA Netw Open. 2023 Dec 1;6(12):e2346494 [PMID: 38060227]
  100. Cancer Biol Ther. 2020 Dec 1;21(12):1128-1135 [PMID: 33190594]
  101. Theranostics. 2021 Aug 18;11(18):8926-8944 [PMID: 34522219]
  102. Cytokine Growth Factor Rev. 2023 Oct;73:150-162 [PMID: 37225643]
  103. Rev Med Virol. 2023 Sep;33(5):e2463 [PMID: 37291746]
  104. Adv Sci (Weinh). 2024 Mar;11(11):e2306373 [PMID: 38204202]
  105. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188488 [PMID: 33271308]
  106. Mol Ther Nucleic Acids. 2022 Apr 27;28:758-791 [PMID: 35664698]
  107. Oncol Lett. 2021 Jan;21(1):54 [PMID: 33281965]
  108. Cancer Lett. 2022 Apr 1;530:45-58 [PMID: 35051533]
  109. J Cell Mol Med. 2021 Jul;25(14):6602-6617 [PMID: 34075693]
  110. Mol Cancer. 2021 Dec 1;20(1):154 [PMID: 34852849]
  111. Blood. 2022 Dec 8;140(23):2429-2442 [PMID: 35271699]
  112. Int J Biol Sci. 2023 Jun 12;19(10):3099-3114 [PMID: 37416779]
  113. Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188728 [PMID: 35385773]
  114. Am J Cancer Res. 2023 May 15;13(5):1999-2012 [PMID: 37293147]
  115. Small. 2021 Sep;17(35):e2007971 [PMID: 34075696]
  116. Matrix Biol. 2023 Apr;118:16-46 [PMID: 36781087]
  117. Adv Healthc Mater. 2023 Jul;12(18):e2203361 [PMID: 36881547]
  118. Int J Biol Sci. 2023 Apr 17;19(7):2198-2219 [PMID: 37151887]
  119. Int J Biol Sci. 2021 Mar 27;17(5):1328-1338 [PMID: 33867849]
  120. J Control Release. 2022 Aug;348:84-94 [PMID: 35649485]
  121. Semin Cancer Biol. 2022 Jan;78:35-44 [PMID: 34757184]
  122. Signal Transduct Target Ther. 2023 Sep 11;8(1):341 [PMID: 37691066]
  123. Ageing Res Rev. 2021 Jul;68:101321 [PMID: 33727157]
  124. Mol Ther Nucleic Acids. 2021 May 19;25:468-482 [PMID: 34589270]
  125. J Exp Clin Cancer Res. 2023 May 23;42(1):131 [PMID: 37217932]
  126. Mol Ther. 2021 Apr 7;29(4):1512-1528 [PMID: 33388421]
  127. Trends Genet. 2023 May;39(5):401-414 [PMID: 36863945]
  128. J Clin Invest. 2023 Sep 15;133(18): [PMID: 37712425]
  129. Front Pharmacol. 2022 Apr 04;13:883445 [PMID: 35444548]
  130. Adv Drug Deliv Rev. 2023 Aug;199:114899 [PMID: 37236425]
  131. Trends Biochem Sci. 2020 Nov;45(11):947-960 [PMID: 32800670]
  132. Mol Cancer. 2021 Mar 29;20(1):57 [PMID: 33781255]
  133. Genome Med. 2020 Sep 2;12(1):77 [PMID: 32878637]
  134. J Exp Clin Cancer Res. 2023 Jun 16;42(1):148 [PMID: 37328828]
  135. Wiley Interdiscip Rev RNA. 2023 Nov-Dec;14(6):e1812 [PMID: 37544928]
  136. Mol Cancer. 2019 Apr 2;18(1):76 [PMID: 30940131]
  137. J Ovarian Res. 2023 May 13;16(1):94 [PMID: 37179363]
  138. Exp Mol Med. 2022 Sep;54(9):1379-1389 [PMID: 36117219]
  139. Cell Cycle. 2023 Oct;22(20):2211-2228 [PMID: 37974391]
  140. Immunopharmacol Immunotoxicol. 2022 Apr;44(2):275-286 [PMID: 35196944]
  141. Cancer Treat Rev. 2023 Jan;112:102489 [PMID: 36446254]
  142. Drugs. 2023 Oct;83(15):1365-1385 [PMID: 37737434]
  143. Bioact Mater. 2021 Aug 28;10:281-294 [PMID: 34901546]
  144. J Control Release. 2022 Aug;348:706-722 [PMID: 35732250]
  145. Small. 2023 Jun 13;:e2300096 [PMID: 37312613]
  146. ACS Nano. 2021 Nov 23;15(11):17047-17079 [PMID: 34723478]
  147. J Hematol Oncol. 2022 Jun 28;15(1):83 [PMID: 35765040]
  148. Future Oncol. 2022 Aug;18(26):2919-2931 [PMID: 35893704]
  149. J Adv Res. 2021 Jan 08;31:61-74 [PMID: 34194832]
  150. J Cancer. 2019 May 12;10(9):1958-1967 [PMID: 31205555]
  151. Mol Pharm. 2023 Nov 6;20(11):5440-5453 [PMID: 37819754]
  152. N Engl J Med. 2023 Jun 8;388(23):2159-2170 [PMID: 36972022]
  153. Nat Rev Cancer. 2022 Nov;22(11):640-656 [PMID: 36109621]
  154. J Nanobiotechnology. 2024 Feb 15;22(1):62 [PMID: 38360615]
  155. Cochrane Database Syst Rev. 2023 Mar 27;3:CD012513 [PMID: 36971688]
  156. Pharmacol Res. 2022 Dec;186:106549 [PMID: 36368452]
  157. Theranostics. 2021 Mar 11;11(11):5330-5345 [PMID: 33859750]
  158. J Ovarian Res. 2020 Apr 26;13(1):47 [PMID: 32336272]
  159. Small. 2021 Dec;17(50):e2101741 [PMID: 34288410]
  160. J Med Virol. 2023 Feb;95(2):e28525 [PMID: 36702772]
  161. Am J Cancer Res. 2021 May 15;11(5):2124-2141 [PMID: 34094673]
  162. Curr Issues Mol Biol. 2022 Jan 09;44(1):288-300 [PMID: 35723400]
  163. Mater Today Bio. 2023 Mar 11;19:100608 [PMID: 36969697]
  164. Cancer Biomark. 2020;27(4):485-491 [PMID: 32065786]
  165. Cancer Cell Int. 2019 Dec 21;19:347 [PMID: 31889899]
  166. Ageing Res Rev. 2023 Jun;87:101913 [PMID: 36934850]
  167. Cell Death Dis. 2021 Aug 30;12(9):818 [PMID: 34462422]
  168. Mol Cancer. 2023 Aug 19;22(1):140 [PMID: 37598158]
  169. J Gynecol Oncol. 2020 Sep;31(5):e75 [PMID: 32808501]
  170. Int J Oral Sci. 2022 Aug 5;14(1):40 [PMID: 35927232]
  171. Dis Markers. 2021 Sep 15;2021:1544784 [PMID: 34567283]
  172. Pharmacol Res. 2021 Jul;169:105680 [PMID: 34010670]
  173. Mol Cancer. 2022 Jan 17;21(1):19 [PMID: 35039054]
  174. Trends Cell Biol. 2024 Jan;34(1):31-47 [PMID: 37419737]
  175. Reprod Sci. 2022 Aug;29(8):2236-2250 [PMID: 35075616]
  176. Oncogene. 2024 Mar;43(10):714-728 [PMID: 38225339]
  177. Mol Cancer. 2021 Jun 2;20(1):83 [PMID: 34078376]
  178. Trends Genet. 2023 Oct;39(10):758-772 [PMID: 37658004]
  179. Cancer Cell Int. 2019 Dec 03;19:323 [PMID: 31827397]
  180. Cytokine Growth Factor Rev. 2023 Oct;73:93-100 [PMID: 37541791]
  181. J Clin Oncol. 2023 Apr 1;41(10):1952-1953 [PMID: 36763910]
  182. Pharmacol Ther. 2023 Aug;248:108466 [PMID: 37301330]
  183. Drug Resist Updat. 2023 Sep;70:100988 [PMID: 37413937]
  184. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188950 [PMID: 37419192]
  185. Acta Pharm Sin B. 2021 Sep;11(9):2783-2797 [PMID: 34589397]
  186. Semin Cancer Biol. 2022 Nov;86(Pt 1):46-57 [PMID: 34343652]

Word Cloud

Created with Highcharts 10.0.0resistancencRNAstumorsgynecologicexosomalcancerbiomarkerscancersTherapeutictumorcellstreatmentmolecularmechanismsExosomesRNAsdrugpotentialtherapyGynecologicincludingovarianOCcervicalCCendometrialECposeseriousthreatwomen'shealthqualitylifeduehighincidencelethalityrefersreducedsensitivitytherapeuticdrugsradiationcompromisesefficacyrendersineffectivesignificantlycontributesfailurealthoughspecificremainunclearnanoscalevesiclesreleasedreceiveddistinctkindscontainproteinslipidscloselylinkedoriginsfunctionsRecentstudiesdemonstratedmayinvolvedintercellularcommunicationcanmodulateprogressiontumorigenesisaggravationmetastasismicroenvironmentTMEBesidesalsobecomesignificantdiagnosticprognosticvariousdiseasespaperreviewedbiologicalroleswellexploredactingliquidbiopsymarkersExosomalnoncodinggynecologicalcancers:implicationsexosomestargeted

Similar Articles

Cited By (1)